Version June 2024
| Patient factors |
| Younger age in children |
| Older age in adults |
| Poor performance status |
| Glutathione S-transferase M1 null genotype |
| Hemochromatosis C282Y allele |
| Pre-existing hepatic dysfunction |
| Hypoalbuminemia |
| Hyperbilirubinemia |
| High serum ferritin |
| Positive CMV serology |
| Elevated plasma transforming growth factor β level |
| Hepatitis B or C infection |
| History of pancreatitis |
| Disease factors |
| Thalassemia major |
| Advanced malignancy |
| Acute leukemia |
| Neuroblastoma |
| Delayed platelet engraftment |
| Presence of acute graft-versus-host disease |
| Treatment factors |
| Interval between diagnosis and transplantation greater than 13 months |
| Allogeneic HCT |
| Unrelated donor HCT |
| Mismatched donor |
| Second or subsequent transplants |
| Prior use of gemtuzumab ozogamicin |
| Prior use of norethisterone |
| Prior abdominal irradiation |
| Use of total parenteral nutrition within 30 days before HCT |
| High dose cytoreductive therapy |
| Conditioning regimen containing busulfan with or without cyclophosphamide |
| Conditioning regimen containing fludarabine |
| Conditioning regimen containing melphalan |
| Total body irradiation |
| Graft-versus-host disease prophylaxis with cyclosporin with or without methotrexate |
| Use of sirolimus |
| Use of tranexamic acid |
| Platelet transfusion containing ABO-incompatible plasma |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
